The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
voxeljet AG (NYSE:VJET) has issued its financial guidance for the year ending.
voxeljet AG (NYSE:VJET) has issued its financial guidance for this year.
According to the press release:
- Revenue is expected to be in the range of 28.0 million and 30.0 million Euros. This compares to revenue guidance for the year ended December 31, 2015 of between 23.0 million and 24.0 million Euros, which the Company is affirming.
- Gross margin is expected to be between 40% and 42%.
- Operating expenses for the full year are expected as follows: SG&A expenses in the range of 10.0 million and 11.0 million Euros, and R&D expenses to be approximately 4.0 million to 5.0 million Euros. Depreciation and amortization expense is expected to be between 3.0 million and 4.0 million Euros.
- EBITDA is expected to be neutral-to-positive in 2016.
- Capital expenditures are projected to be in the range of 12.0 million to 13.0 million Euros, which primarily includes ongoing investments in our global subsidiaries.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â